Mouse Anti-Human LIF Monoclonal Antibody Datasheet

Product Name: mAb anti-human LIF Clone No.: 3F4

Catalogue No.: MO-C40096B Quantity:

Description: Mouse monoclonal antibody to human

Leukemia inhibitory factor (LIF).

Purification: Protein G affinity purified

Product Type: Primary antibody

Target Protein: LIF

Immunogen: Recombinant LIF

Fusion Sp2/0-Ag14

Myeloma:

Specificity: This antibody is reactive to recombinant

human LIF protein.

Species Human, others not tested

Reactivity:

Host / Isotype: Mouse, IgG2b Kappa

Formulation: Lyophilized from a solution in 0.01M

PBS, pH 7.0

Reconstitution: Double distilled water is recommended

to adjust the final concentration to

1mg/mL.

Storage: Store at -20°C

Research Area: Cytokine and oncology

Background: LIF is a cytokine with important

functions in diversified biological processes including cell differentiation, inflammatory response, neuronal development and cancer progression.

LIF can induce the terminal

differentiation of leukemia cells, thus it

inhibits the further progression of leukemia. However, it has opposite effects on many other cancers, such as breast cancer and bladder cancer etc. Several recent studies have shown that LIF might play a significant role in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis development. Treatment of pancreatic cancer by blocking LIF is currently under investigation. Research also demonstrated that elevated LIF level in pancreatic tissue and circulation was correlated with the cancer progression,


Applications:

Western blot: This antibody detected recombinant LIF protein on Western

indicating that LIF might be useful as a

Blot.

biomarker.



This product is for LABORATORY RESEARCH USE and further manufacture ONLY, and cannot be administrated to human and animals for use in diagnostic and therapeutic procedures.

Manufactured by ANOGEN - A Division of YES Biotech Laboratories Ltd.

The antibody can detect less than 10ng/well of recombinant LIF on the blot.

EIA: This antibody is reactive to recombinant human LIF in indirect ELISA.

References:

Xuetian Yue et al., The regulation of leukemia inhibitory factor. Cancer Cell Microenvironment 2015; 2(3): e877.

Yu Shi et al., Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature 2019 569 (131–135),

Christian Bressy et al., LIF drives neural remodeling in pancreatic cancer and offers a New Candidate Biomarker 2018 15:78(4):909-921

If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.